Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.84 USD
Change Today -0.03 / -1.60%
Volume 153.4K
PTIE On Other Exchanges
Symbol
Exchange
PTIE is not on other exchanges.
As of 5:20 PM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

pain therapeutics inc (PTIE) Key Developments

Pain Therapeutics Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Net Cash Guidance for the Year 2015

Pain Therapeutics Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company’s net loss was $2.2 million, or $0.05 per basic and diluted share, compared to a net income of $33.02 million, or $0.72 per diluted share, a year ago. Operating loss was $2.2 million, compared to an operating income of $32.903 million a year ago. Loss before provision for income taxes was $2.2 million against income of $32.942 million a year ago. For the year the company’s net loss was $12.4 million, or $0.27 per basic and diluted share, compared to a net income of $31.5 million, or $0.70 per basic and diluted share, a year ago. Operating loss was $12.433 million, compared to an operating income of $31.4 million a year ago. Loss before provision for income taxes was $12.4 million against income of $31.5 million a year ago. Net cash used in 2014 was $9.2 million. In 2015, the company expects net cash usage to be approximately $12 million.

Pain Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Pain Therapeutics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net loss of $3.5 million, or $0.08 per basic and diluted share, compared to a net loss of $0.8 million, or $0.02 per basic and diluted share in last year. The company reported operating loss of $3.5 million compared to $0.8 million for the last year. For the nine months, the company reported net loss of $10.2 million, or $0.23 per basic and diluted share, compared to a net loss of $1.5 million, or $0.03 per basic and diluted share and operating loss of $10.3 million compared to $1.5 million for the last year.

Pain Therapeutics Inc. - Special Call

To discuss regain of full rights to REMOXY

Pfizer to Discontinue Agreement on REMOXY(TM) (oxycodone) Extended-Release Capsules CII with Pain Therapeutics

Pfizer Inc. has notified Pain Therapeutics Inc. that it has decided to discontinue its agreement to develop and commercialize REMOXY(TM) (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics Inc. Pfizer has concluded an internal review of the top-line results of five recently completed clinical studies required to address the Complete Response Letter received in June 2011 from the U.S. Food and Drug Administration (FDA). Pfizer and Pain Therapeutics Inc. will work together for an orderly transition of REMOXY to Pain Therapeutics Inc. Pfizer will continue ongoing activities under the agreement for the next six months until the scheduled termination date.

Pain Therapeutics Inc., Q3 2014 Earnings Call, Oct 30, 2014

Pain Therapeutics Inc., Q3 2014 Earnings Call, Oct 30, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTIE:US $1.84 USD -0.03

PTIE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTIE.
View Industry Companies
 

Industry Analysis

PTIE

Industry Average

Valuation PTIE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAIN THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.